Publicité
Vivalytic C. difficile
References
Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium
1
difficile; EU Member States; European Centre for Disease Prevention and
Control. Emergence of Clostridium difficile-associated disease in North
America and Europe. Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18.
Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A,
2
Goldman S, Wultańska D, Garlicki A, Biesiada G. Clostridium difficile
infection: review. Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1211-1221.
doi: 10.1007/s10096-019-03539-6. Epub 2019 Apr 3. PMID: 30945014;
PMCID: PMC6570665.
Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms
3
of action and antitoxin therapeutics. Nat Rev Microbiol. 2022 May; 20(5):
285-298.
Gerding DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile binary
4
toxin CDT: mechanism, epidemiology, and potential clinical importance.
Gut Microbes. 2014 Jan-Feb; 5(1): 15-27.
COPAN Instructions for Use of Copan eNAT® Collection and Preservation
5
System; Version EIFU002R01 Date 2021.06.
Symbols
Manufacturer
Date of manufacture
Expiry date
Lot number
Reference number
Contains <n> tests
CE mark
Pipette the indicated sample volume in the sample input of the
30 0 µ l
cartridge as marked by the black triangle.
– Instructions for Use
7
Serial number
Temperature limit
Do not use if package is damaged
For single use only
Consult Instructions for Use
in vitro diagnostic medical device
Publicité
